XFOR

X4 Pharmaceuticals, Inc. (XFOR) - 10-Q Summary for Period Ended June 30, 2025

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the three and six months ended June 30, 2025. X4 Pharmaceuticals is a biopharmaceutical company focused on rare immune system diseases. Its primary commercial product is XOLREMDI (mavorixafor), approved by the FDA for WHIM syndrome. The company also has a pivotal Phase 3 trial (4WARD) ongoing for chronic neutropenia. Notably, the company effected a 1-for-30 reverse stock split on April 28, 2025, and all share data in this report is retroactively adjusted.

Key Financial Metrics

Note: Revenue for the six months ended June 30, 2025, includes a significant one-time license revenue of approximately $27.6 million from the Norgine Agreement.

Material Changes vs. Prior Period

• Revenue Surge: Total revenue for the six months ended June 30, 2025, increased to $30.8 million from $0.6 million in the prior year period. This is primarily driven by the recognition of $27.6 million in license revenue from the Norgine Agreement (exclusive license for EEA, UK, Australia, NZ) and $0.5 million in R&D services revenue. Product revenue from XOLREMDI sales was $2.7 million for the six months ended June 30, 2025, compared to $0.6 million in the prior year.
• Net Loss vs. Net Income: The company reported a net loss of $25.5 million for the six months ended June 30, 2025, compared to a net income of $39.1 million in the same period in 2024. The 2024 income was significantly boosted by a $105 million gain on the sale of a Priority Review Voucher (PRV), which did not recur in 2025.
• Expense Reduction: Research and Development (R&D) expenses decreased by $3.8 million year-over-year for the six-month period, and Selling, General, and Administrative (SG&A) expenses decreased by $6.1 million. These reductions are attributed to the "2025 Strategic Restructuring," which included a 30% workforce reduction and the closure of the Vienna, Austria facility.
• Warrant Liability Gain: The company recognized a non-cash gain of $13.5 million related to the change in fair value of the Class C warrant liability, compared to $6.5 million in the prior year period.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern Warning: Management has concluded that there is substantial doubt about the company's ability to continue as a going concern for the next 12 months. Current cash and marketable securities ($63.0 million) are insufficient to fund operations and meet debt covenants without additional financing.
• Debt Covenants: The company is subject to a "Minimum Cash Covenant" requiring $15.0 million in cash (20% of outstanding borrowings) and a "Performance Covenant" based on trailing six-month net product revenue. Management believes it will not meet these covenants under the current operating plan, which could trigger an acceleration of debt repayment by Hercules Capital Inc.
• Capital Raising: To mitigate covenant risks and fund operations, the company entered into a Purchase Agreement with Lincoln Park Capital Fund, LLC, allowing for the sale of up to $40.0 million of common stock over 24 months. As of June 30, 2025, $0.5 million had been raised under this agreement.
• Strategic Restructuring: The company implemented a restructuring in Q1 2025, reducing headcount by 43 employees and closing the Vienna facility. This is expected to decrease annual spending by $30–$35 million.
• Regulatory Progress: The FDA granted Fast Track designation for mavorixafor for chronic neutropenia in June 2025. The company is awaiting EMA validation for WHIM syndrome in the EU.

Key Facts for Investor Verification

• Liquidity Runway: Verify the company's ability to raise additional capital immediately to satisfy the Hercules Loan Agreement covenants and avoid default/acceleration of the $75 million debt.
• Revenue Sustainability: Distinguish between the one-time $27.6 million license revenue from Norgine and the recurring product revenue from XOLREMDI ($2.7 million for six months) to assess true commercial traction.
• Debt Structure: Review the terms of the Hercules Loan Agreement, specifically the "Minimum Cash Covenant" and "Performance Covenant," and the potential consequences of default.
• Restructuring Impact: Monitor the actual cost savings realized from the 2025 Strategic Restructuring and the impact of the Vienna facility closure on R&D timelines.
• Stock Split Effects: Confirm that all share counts and per-share metrics in the filing have been correctly adjusted for the 1-for-30 reverse stock split effective April 28, 2025.